December 2007 Cover
|
 |
Johnson & Johnson's Prezista was as effective as Abbott Laboratories' Kaletra in reducing HIV to undetectable levels in a population of treatment- naive patients, according to a
new study.
Prezista was introduced last year as a treatment for adults whose HIV infections were not responding adequately to other HIV drugs. Based on the new data, the company plans to ask
US regulators this year to approve it for patients just starting HIV drug therapy.
In the current trial, one group of patients received the protease inhibitor Prezista in an experimental 800-milligram once-daily dose, along with Abbott's older protease inhibitor
Norvir (ritonavir) and Truvada. The other group of patients received Kaletra, which combines Norvir with the protease inhibitor lopinavir, plus Truvada.
The Johnson & Johnson researchers said 84 percent of the Prezista patients had achieved undetectable HIV levels after 48 weeks, compared with 78 percent of the Kaletra patients.
from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
